Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Zaloumis, Sophie ^a   Humberstone, Andrew ^b   Charman, Susan A ^c   Price, Ric N ^d,e   Moehrle, Joerg ^b   Gamo Benito, Javier ^f   McCaw, James ^a   Jamsen, Kris M ^a   Smith, Katherine ^g,h   Simpson, Julie A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Medicines for Malaria Venture   (Switzerland)

^c MONASH UNIVERSITY   (Australia)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f Tres Cantos Medicines Development Campus ^*  (Spain)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anti malarial combination therapy; Pharmacokinetic pharmacodynamic model; Plasmodium falciparum

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE;

ANTIMALARIAL ACTIVITY; ARTICLE; ASEXUAL REPRODUCTION; DRUG BLOOD LEVEL; HOST PARASITE INTERACTION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALARIA; NONHUMAN; PARASITE CLEARANCE; PARASITE LOAD; PLASMA PROTEIN BINDING; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG DISCOVERY; ETHANOLAMINES; FLUORENES; HOST-PATHOGEN INTERACTIONS; HUMANS; MALARIA, FALCIPARUM; MEFLOQUINE; MODELS, STATISTICAL; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 84865458780     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-303     Document Type: Article

References (30)

1. WHO, World Malaria Report 2011 Geneva 2011 Geneva: Available: http://www.who.int/malaria/world-malaria-report-2011/en/
2. WHO, Guidelines for the treatment of malaria Geneva 2 2010 Available: http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html
3. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
4. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L, Clin Infect Dis 2010 51 82 e89 10.1086/657120 21028985
5. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ, Antimicrob Agents Chemother 2000 44 3414 3424 10.1128/AAC.44.12.3414- 3424.2000 11083649 (Pubitemid 33009503)
6. Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine. Hoshen MB, Stein WD, Ginsburg HD, Parasitology 2001 123 337 346 11676365 (Pubitemid 32937924)
7. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H, Parasitology 2000 121 Pt 3 237 246 11085244
8. Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Hoshen MB, Stein WD, Ginsburg H, Parasitology 1998 116 Pt 5 407 416 9614323 (Pubitemid 28221660)
9. Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Hoshen MB, Stein WD, Ginsburg H, Parasitology 2002 124 9 15 11811806 (Pubitemid 34816180)
10. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegardh N, Chotivanich K, Nosten F, Day NP, Socheat D, White NJ, Dondorp AM, White LJ, Proc Natl Acad Sci U S A 2011 108 397 402 10.1073/pnas.1006113108 21173254
11. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Hoare A, Regan DG, Wilson DP, Theor Biol Med Model 2008 5 4 10.1186/1742-4682-5-4 18304361 (Pubitemid 351514712)
12. R, Development, Core, Team, R: A language and environment for statistical computing Austria: R Foundation for Statistical Computing V 2009
13. In Vitro Interactions between Piperaquine, Dihydroartemisinin, and Other Conventional and Novel Antimalarial Drugs. Davis TME, Hamzah J, Ilett KF, Karunajeewa HA, Reeder JC, Batty KT, Hackett S, Barrett PHR, Antimicrob Agents Chemother 2006 50 2883 2885 10.1128/AAC.00177-06 16870794 (Pubitemid 44198722)
14. The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Fivelman QL, Waiden JC, Smith PJ, Folb PI, Barnes KI, Trans R Trop Med Hyg 1999 93 429 432 10.1016/S0035-9203(99)90147-5 (Pubitemid 29405878)
15. Synergism of benflumetol and artemether in Plasmodium falciparum. Hassan Alin M, Björkman A, Wernsdorfer WH, Am J Trop Med Hyg 1999 61 439 445 10497987 (Pubitemid 29428717)
16. Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Jamsen K, Duffull S, Tarning J, Lindegardh N, White N, Simpson J, Malar J 2011 10 181 10.1186/1475-2875-10- 181 21722356
17. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Ezzet F, Mull R, Karbwang J, Br J Clin Pharmacol 1998 46 553 561 9862244 (Pubitemid 28522119)
18. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Hutagalung R, Hae R, Singhasivanon P, White NJ, Nosten F, Antimicrob Agents Chemother 2006 50 2281 2285 10.1128/AAC.00040-06 16801402 (Pubitemid 43993164)
19. Population Pharmacokinetics of Piperaquine after Two Different Treatment Regimens with Dihydroartemisinin-Piperaquine in Patients with Plasmodium falciparum Malaria in Thailand. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, McGready R, Ashton M, Nosten F, White NJ, Antimicrob Agents Chemother 2008 52 1052 1061 10.1128/AAC.00955-07 18180343 (Pubitemid 351358388)
20. Mathematical model of the first wave of Plasmodium falciparum asexual parasitemia in non-immune and vaccinated individuals. Dietz K, Raddatz G, Molineaux L, Am J Trop Med Hyg 2006 75 46 55 16931815
21. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Simpson JA, Aarons L, Collins WE, Jeffery GM, White NJ, Parasitology 2002 124 247 263 11922427 (Pubitemid 34250739)
22. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ, J Infect Dis 1992 166 1393 1400 10.1093/infdis/166.6.1393 1431257
23. Cousin M, Kummerer S, Lefevre G, Marrast AC, Stein D, Weaver M, Coartem (artemether-lumefantrine) Tablets for the treatment of malaria in patients with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum Novartis: Advisory Committee Briefing Book 2008
24. P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action. Sanz LM, Crespo B, De-Cozar C, Ding XC, Llergo JL, Burrows JN, Garcia-Bustos JF, Gamo FJ, PLoS One 2012 7 30949 10.1371/journal.pone.0030949 22383983
25. Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture. Geary TG, Divo AA, Jensen JB, Am J Trop Med Hyg 1989 40 240 244 2648881 (Pubitemid 19111604)
26. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Russell B, Chalfein F, Prasetyorini B, Kenangalem E, Piera K, Suwanarusk R, Brockman A, Prayoga P, Sugiarto P, Cheng Q, Tjitra E, Anstey NM, Price RN, Antimicrobial Agents Chemother 2008 52 1040 1045 10.1128/AAC.01334-07 (Pubitemid 351358386)
27. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, Antimicrob Agents Chemother 1979 16 710 718 10.1128/AAC.16.6.710 394674 (Pubitemid 10082023)
28. Randomized, controlled dose-optimization studies of dihydroartemisinin- piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ, J Infect Dis 2004 190 1773 1782 10.1086/425015 15499533 (Pubitemid 39487822)
29. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ, Nosten F, Clin Infect Dis 2005 41 425 432 10.1086/432011 16028147 (Pubitemid 41099632)
30. (Pubitemid 30117964)